CD70 CAR T cells in AML: Form follows function

Justin Mirazee; Nirali N Shah

doi:10.1016/j.xcrm.2022.100639

CD70 CAR T cells in AML: Form follows function

Cell Rep Med. 2022 May 17;3(5):100639. doi: 10.1016/j.xcrm.2022.100639.

Authors

Justin Mirazee¹, Nirali N Shah²

Affiliations

¹ Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Johns Hopkins University Department of Biology, 3400 N. Charles Street, Baltimore, MD, USA.
² Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: nirali.shah@nih.gov.

Abstract

Using a multimodal approach toward developing a new CD70-targeted Chimeric antigen receptor (CAR) T cell in acute myeloid leukemia, Leick et al.¹ report on their synergetic strategy, which incorporates both CAR T cell construct modifications with enhancement of leukemia antigen expression to improve CAR T cell functionality.

Published by Elsevier Inc.

Publication types

Research Support, N.I.H., Intramural
Comment

MeSH terms

CD27 Ligand* / genetics
CD27 Ligand* / immunology
Humans
Immunotherapy, Adoptive*
Leukemia, Myeloid, Acute* / immunology
Leukemia, Myeloid, Acute* / therapy
Receptors, Chimeric Antigen* / genetics
Receptors, Chimeric Antigen* / immunology
T-Lymphocytes / immunology

Substances

CD27 Ligand
CD70 protein, human
Receptors, Chimeric Antigen

Grants and funding

ZIA BC011927/ImNIH/Intramural NIH HHS/United States